Dane Leone
Stock Analyst at Raymond James
(1.20)
# 3,756
Out of 5,146 analysts
69
Total ratings
33.96%
Success rate
-6.1%
Average return
Main Sectors:
Stocks Rated by Dane Leone
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLAY Relay Therapeutics | Maintains: Strong Buy | $29 → $19 | $9.16 | +107.42% | 3 | Aug 8, 2025 | |
| XLO Xilio Therapeutics | Maintains: Outperform | $6 → $4 | $0.54 | +643.77% | 3 | Nov 8, 2024 | |
| RGNX REGENXBIO | Reinstates: Outperform | $45 | $8.75 | +414.29% | 2 | Feb 21, 2024 | |
| RVMD Revolution Medicines | Initiates: Outperform | $30 | $102.15 | -70.63% | 1 | Nov 16, 2023 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $950 | $770.79 | +23.25% | 10 | Nov 3, 2023 | |
| NKTX Nkarta | Upgrades: Strong Buy | $13 | $2.62 | +396.18% | 5 | Oct 18, 2023 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $29 → $46 | $67.61 | -31.96% | 2 | Jul 18, 2023 | |
| GLPG Galapagos NV | Upgrades: Outperform | $69 | $33.49 | +106.03% | 5 | May 8, 2023 | |
| CMPX Compass Therapeutics | Maintains: Outperform | $5 → $8 | $5.78 | +38.41% | 2 | Nov 10, 2022 | |
| OCUL Ocular Therapeutix | Maintains: Strong Buy | $29 → $14 | $9.59 | +45.99% | 5 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $58 | $13.55 | +328.04% | 4 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $70 | $12.09 | +478.99% | 3 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.73 | - | 6 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $63 | $62.63 | +0.59% | 2 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $61.10 | - | 4 | Jun 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.11 | - | 2 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $50 → $65 | $75.87 | -14.33% | 3 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $255 | $379.33 | -32.78% | 3 | Oct 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $32 | $4.23 | +656.50% | 2 | Sep 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $243.47 | - | 2 | Jul 21, 2017 |
Relay Therapeutics
Aug 8, 2025
Maintains: Strong Buy
Price Target: $29 → $19
Current: $9.16
Upside: +107.42%
Xilio Therapeutics
Nov 8, 2024
Maintains: Outperform
Price Target: $6 → $4
Current: $0.54
Upside: +643.77%
REGENXBIO
Feb 21, 2024
Reinstates: Outperform
Price Target: $45
Current: $8.75
Upside: +414.29%
Revolution Medicines
Nov 16, 2023
Initiates: Outperform
Price Target: $30
Current: $102.15
Upside: -70.63%
Regeneron Pharmaceuticals
Nov 3, 2023
Upgrades: Outperform
Price Target: $950
Current: $770.79
Upside: +23.25%
Nkarta
Oct 18, 2023
Upgrades: Strong Buy
Price Target: $13
Current: $2.62
Upside: +396.18%
BridgeBio Pharma
Jul 18, 2023
Maintains: Outperform
Price Target: $29 → $46
Current: $67.61
Upside: -31.96%
Galapagos NV
May 8, 2023
Upgrades: Outperform
Price Target: $69
Current: $33.49
Upside: +106.03%
Compass Therapeutics
Nov 10, 2022
Maintains: Outperform
Price Target: $5 → $8
Current: $5.78
Upside: +38.41%
Ocular Therapeutix
Nov 8, 2022
Maintains: Strong Buy
Price Target: $29 → $14
Current: $9.59
Upside: +45.99%
Oct 13, 2022
Upgrades: Strong Buy
Price Target: $58
Current: $13.55
Upside: +328.04%
Aug 29, 2022
Maintains: Outperform
Price Target: $54 → $70
Current: $12.09
Upside: +478.99%
Aug 10, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $2.73
Upside: -
Aug 5, 2022
Maintains: Outperform
Price Target: $54 → $63
Current: $62.63
Upside: +0.59%
Jun 6, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $61.10
Upside: -
Apr 5, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.11
Upside: -
Oct 8, 2021
Maintains: Strong Buy
Price Target: $50 → $65
Current: $75.87
Upside: -14.33%
Oct 26, 2020
Upgrades: Outperform
Price Target: $255
Current: $379.33
Upside: -32.78%
Sep 10, 2018
Assumes: Buy
Price Target: $32
Current: $4.23
Upside: +656.50%
Jul 21, 2017
Downgrades: Sell
Price Target: n/a
Current: $243.47
Upside: -